Novel drugs are being developed which interact with the programmed cell death (apoptotic) machinery in cancer cells, thereby causing these cells to commit suicide and to be removed from the body. Research is also directed to investigate why the cancer cells sometimes lose the ability to undergo apoptosis after a certain period of time and methods are being developed to reactivate this cell death process. This book is intended for workers in the field and clinicians as a useful guide of the state of affairs in this exciting field which may offer more effective possibilities for treatment of cancer patients.Mels Sluyser is the Editor of the journals APOPTOSIS and ANTI-CANCER DRUGS. He brings together a collection of papers written by the world¿s leading experts in these fields.

Chapter 1: Disfunction of the Apoptotic Pathway in Cancer Cells by Lily Yang Chapter 2: Calcium Signaling and Apoptosis Resistance of Cancer Cells by Natalia Prevarskaya, Roman Skryma and Yaroslav Shuba Chapter 3: Cell Clearance and Cancer by Bengt Fadeel Chapter 4: Specific, Pro-Poptotic Cell-Signaling: Design of Novel, Recombinant Targeted Antitumor Agents Operating Exclusively Through Modulation of Cellular Apoptotic Events: Novel, Targeted Pro-Apoptotic Therapeutic Agents by Yuying Liu, Lawrence H. Cheung and Michael G. Rosenblum Chapter 5: Targeting Oncogenes which Regulate Apoptosis by Andrew C. Phillips Chapter 6: Targeting Cyclins to Cause Cancer Cell Apoptosis by Suparna Mazumder, Dragos Plesca and Alexandru Almasan Chapter 7: Apoptosis Induction by Tumor-Targeted Toxins by Andrew Thorburn Chapter 8: Targeting Cell-Death Pathways in Multiple Myeloma: Therapeutic Implications by Dharminder Chauhan and Kenneth Anderson Chapter 9: Cephalostatin 1-Induced Apoptosis in Tumor Cells Selective Induction of Smac/DIABLO Release by Verena M. Dirsch and Angelika M. Vollmar Chapter10: Hamlet; a Novel Tool to Identify Apoptotic Pathways in Tumor Cells 223 by Caroline Düringer, Oskar Hallgren, Lotta Gustafsson, Jenny Petterson, Ann-Kristin Mossberg, Taras Manilov and Catharina Svanborg Chapter 11: Cancer Immunotherapy: On the Trail of a Cure? by Thomas S. Griffith, Troy J. Kemp1, Aaron T. Ludwig, Jill M. Moore, and Rebecca L. VanOosten Chapter 12: Histone Deacetylase Inhibitors as a Treatment of Trail-Resistant Cancers by Jiri Neuzil, Ladislav Andera and Brian Gabrielli Chapter 13: Basis of Cell Kill Following Clinical Radiotherapy by Oliver Faulhaber and Robert G Bristow Chapter 14: Imaging of Apoptotic Cells in Vivo by Juhana Hakumäki Chapter15: Apoptosis-Inducing Anticancer Drugs in Clinical Trials by Wei Hu and John J. Kavanagh